November 2001
1289
7
)
Sashida Y., Kubo S., Mimaki Y., Nikaido T., Ohmoto T., Phytochem-
istry, 31, 2439—2443 (1992).
8
9
)
)
Yokosuka A., Mimaki Y., Sashida Y., J. Nat. Prod., submitted.
Mimaki Y., Kuroda M., Obata Y., Sashida Y., Kitahara M., Yasuda A.,
Naoi N., Xu Z.-W., Li M.-R., Lao A.-N., Nat. Prod. Lett., 14, 357—
3
64 (2000).
1
1
0) Mimaki Y., Sashida Y., Chem. Pharm. Bull., 38, 3055—3059 (1990).
1) Mimaki Y., Kuroda M., Fukasawa T., Sashida Y., J. Nat. Prod., 62,
1
94—197 (1999).
1
1
1
1
1
2) Kanmoto T., Mimaki Y., Sashida Y., Nikaido T., Koike K., Ohmoto T.,
Chem. Pharm. Bull., 42, 926—931 (1994).
3) Mimaki Y., Kuroda M., Fukasawa T., Sashida Y., Chem. Pharm. Bull.,
4
7, 738—743 (1999).
4) Mimaki Y., Kuroda M., Sashida Y., Natural Medicines, 53, 134—137
1999).
(
5) Mimaki Y., Takaashi Y., Kuroda M., Sashida Y., Nikaido T., Phyto-
chemistry, 42, 1609—1615 (1996).
6) Mimaki Y., Kuroda M., Kameyama A., Yokosuka A., Sashida Y.,
Chem. Pharm. Bull., 46, 298—303 (1998); idem, Phytochemistry, 48,
4
85—493 (1998).
1
1
1
2
2
2
2
7) Mimaki Y., Kuroda M., Ide A., Kameyama A., Yokosuka A., Sashida
Y., Phytochemistry, 50, 805—813 (1999).
8) Mimaki Y., Kuroda M., Yokosuka A., Sashida Y., Natural Medicines,
5
2, 374 (1998).
9) Yokosuka A., Mimaki Y., Sashida Y., J. Nat. Prod., 63, 1239—1243
2000).
(
0) Rumyantseva G. N., Fonin V. S., Kalunyants K. A., Shain S. S., Ko-
dash A. G., Prikl. Biokhim. Mikrobiol., 14, 759—766 (1978).
1) Nakamura T., Komori C., Lee Y.-Y., Hashimoto F., Yahara S., Nohara
T., Ejima A., Biol. Pharm. Bull., 19, 564—566 (1996).
Fig. 6
2) Hirai Y., Konishi T., Sanada S., Ida Y., Shoji J., Chem. Pharm. Bull.,
3
0, 3476—3484 (1982).
3) Yahara S., Ura T., Sakamoto C., Nohara T., Phytochemistry, 37, 831—
Therapeutics Program, National Cancer Institute, Bethesda,
MD, for performing the cytotoxic screening studies.
835 (1994).
24) Sargent J. M., Taylor C. G., Br. J. Cancer, 60, 206—210 (1989).
2
5) Goodman J. M., Still W. C., J. Comput. Chem., 12, 1110—1117
1991).
(
REFERENCES AND NOTES
2
6) Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D.,
Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M.,
Campbell H., Mayo J., Boyd M., J. Natl. Cancer Inst., 83, 757—766
1
)
)
Nakashima N., Kimura I., Kimura M., Matsuura H., J. Nat. Prod., 56,
45—350 (1993).
Wu R.-T., Chiang H.-C., Fu W.-C., Chien K.-Y., Chung Y.-M., Horng
L.-Y., Int. J. Immunopharmacol., 12, 777—786 (1990).
3
(
1991).
2
2
7) The LC50 is the concentration at which only 50% of the cells are vi-
able, the GI50 value is the concentration that yields 50% cell growth,
and the TGI is the concentration at which no growth is observed.
3
4
)
)
Miyata T., J. Trad. Sino-Jpn. Med., 13, 276—281 (1992).
Niwa A., Takeda O., Ishimaru M., Nakamoto Y., Yamasaki K., Kohda
H., Nishio H., Segawa T., Fujimura K., Kuramoto A., Yakugaku
Zasshi, 108, 555—561 (1988); Dong J.-X., Han G.-Y., Planta Medica,
2
8) Furuya S., Takayama F., Mimaki Y., Sashida Y., Satoh K., Sakagami
H., Anticancer Res., 20, 4189—4194 (2000); idem, ibid., 21, 959—
9
64 (2001).
5
7, 460—462 (1991).
2
3
9) Candra E., Matsunaga K., Fujiwara H., Mimaki Y., Kuroda M.,
Sashida Y., Ohizumi Y., J. Pharm. Pharmacol., accepted.
0) Ikeda T., Ando J., Miyazono A., Zhu X. -H., Tsumagari H., Nohara T.,
Yokomizo K., Uyeda M., Biol. Pharm. Bull., 23, 363—364 (2000).
5
)
)
Mimaki Y., Nakamura O., Sashida Y., Nikaido T., Ohmoto T., Phyto-
chemistry, 38, 1279—1286 (1995).
Mimaki Y., Satou T., Ohmura M., Sashida Y., Natural Medicines, 50,
6
3
08 (1996).